刘世蒙

1. 卫生技术评估
2. 健康偏好测量
3. 医院管理

1. 卫生技术评估理论与方法
2. 多学科视角的全球卫生
3. 医院管理理论与方法

1. The Patient编委
2. BMC Public Health编委
3. Discover Public Health编委
4. Integrative Medicine Research编委
5. Humanities&Social Sciences Communications编委
6. Science in One Health青年编委
7. PharmacoEconomics and Policy青年编委
8. 中国医保研究会药物经济专委会委员
9. 中国卫生经济学会公共卫生经济专委会委员
10. 中国卫生经济学会卫生技术经济评价专委会委员
11. 中国医药教育协会医疗保障与药物经济学评价分会青年委员

1. 上海市超级博士后

2. 复旦大学超级博士后

3. 复旦大学优秀博士后

1. Shimeng Liu，Yingyao Chen*，Ying Tao，Dai Lian，Shan Jiang，Shunping Li，Yuanyuan Gu. Is best-worst scaling suitable for patient preference elicitation? A nationwide representative comparison with discrete choice experiments among patients with type 2 diabetes in China. BMJ Public Health, 2026.
2. Yuliang Xiang, Liu Liu, Jing Liu , Xiong Ke, Yanfeng Ren, Shiyi Bao, Fuming Li, Shimeng Liu*, Yingyao Chen*. Is there any difference in Preferences Between Patients and Physicians？Evidence from Anti-Hyperglycemic Medications Choices for Type 2 Diabetes. Journal of Diabetes, 2026.
3. Lian D, Liu J, Wei Y, Yang Y, Ren Y, Bao S, Liu L, Shimeng Liu*, Chen Y*. Eliciting Patient-Centric Value Parameters: A National Best-Worst Scaling Profile Case Survey for Second-Line Antidiabetic Drugs in China. Patient. 2025 Nov 5. doi: 10.1007/s40271-025-00776-0. Epub ahead of print. PMID: 41191278.
4. Qiao J, Shimeng Liu *, Bao S, Tao Y, Zhao J, Chen Y. What Matters Most to Patients with NSCLC When Choosing Anticancer Treatments in China? A Best-Worst Scaling Study. Patient Prefer Adherence. 2026 Mar 16;20:584024. doi: 10.2147/PPA.S584024.
5. Xiuyuan Zhu, Zian Ni, Shiyu Xie*, Shimeng Liu *, Xiaogaung Yang*. Factors Affecting Fertility Preferences among Chinese Women of Childbearing Age: A Multi-Center Best-Worst Scaling (BWS) Survey. Humanities&Social Sciences Communications, 2026
6. Gan Y, Zhu Z, Yan J, Peng Y, Gu Y, Chen Y, Shimeng Liu *, He L, Wei Y. Trade-offs between disease label and treatment options: The case of low risk papillary thyroid cancer. Patient Educ Couns. 2026; 148:109532. doi: 10.1016/j.pec.2026.109532.
7. Lian D, Suo Y, Gai R, Li N, Ren Y, Xiao D, Zhao J, Zhang M, Shimeng Liu *, Chen Y*. Renal denervation for hypertension: cross-country cost-effectiveness insights from mainland China, Japan, and Thailand. Health Econ Rev. 2025 Aug 13;15(1):69. doi: 10.1186/s13561-025-00669-w.
8. Li F, Xiao D, Xia Y, Weng J, Shimeng Liu *, Chen Y*. Cost-Effectiveness of Antiarrhythmic Drugs for Treating Paroxysmal or Persistent Atrial Fibrillation in China: An Economic Evaluation. Clin Ther. 2025 Sep;47(9):746-753. doi: 10.1016/j.clinthera.2025.06.011.
9. Deng Q, Shimeng Liu*, Yang Y, Chen Y*. Mind matters: a comparative study of self-reported severity of depression and cognitive symptoms in China and the USA. BMC Public Health. 2025 Mar 21;25(1):1088. (JCR 1区，IF=3.6)
10. Shimeng Liu, Xiang Y, Gu Y, Chen N, Fu P, Wei Y, Zhao P, Li Y, Du C, Mu W, Zhiyuan Xia*, Yingyao Chen*. Patient preferences and willingness to pay for central venous access devices in breast cancer: A multicenter discrete choice experiment. Int J Nurs Stud. 2024;152:104695. (中科院1区Top，IF=8.1).
11. Shimeng Liu, Xia Y, Yang Y, Ming J, Sun H, Wei Y*, Chen Y*. Mapping of health technology assessment in China: a comparative study between 2016 and 2021. Glob Health Res Policy. 2024;9(1):4. (中科院2区，IF=8.7).
12. Shimeng Liu, Liu J, Si L, Ke X, Liu L, Ren Y, Bao S, Li F, Yu Y, Pan Q, Wei Y, Chen Y. Patient preferences for anti-hyperglycaemic medication for type 2 diabetes mellitus in China: findings from a national survey. BMJ Global Health. 2023;8(4):e010942. (中科院1区，IF=8.1).
13. Wang L#, Shimeng Liu#, Jiang S, Li C, Lu L, Fang Y, Li S*. Quantifying Benefit-Risk Trade-Offs Toward Prophylactic Treatment Among Adult Patients With Hemophilia A in China: Discrete Choice Experiment Study. JMIR Public Health Surveill. 2023;9:e45747. (中科院2区，IF=8.5)
14. Yuliang Xiang, Yingyao Chen, Zian Xu, Shanyan Zhou, Zhiyong Qin, Lingchao Chen, Dunming Xiao, Shimeng Liu*. Real‑world cost‑ effectiveness analysis: Tumor treating fields for newly diagnosed glioblastoma in China. Journal of Neuro-Oncology. 2024. doi.org/10.1007/s11060-024-04662-x. 
15. Li F, Shimeng Liu*, Gu Y, Li S, Tao Y, Wei Y, Chen Y*. Comparing the Self-Reported Acceptability of Discrete Choice Experiment and Best-Worst Scaling: An Empirical Study in Patients with Type 2 Diabetes Mellitus. Patient Prefer Adherence. 2024 Aug 30;18:1803-1813.
16. Lian D, Gan Y, Xiao D, Xuan D, Shimeng Liu*, Wei Y*. Cost-effectiveness of first-line systemic therapies for unresectable hepatocellular carcinoma. Br J Clin Pharmacol. 2024 Dec 18. doi: 10.1111/bcp.16367.
17. Lian D, Gan Y, Xiao D, Xuan D, Shimeng Liu*, Wei Y*. Cost-effectiveness of first-line systemic therapies for unresectable hepatocellular carcinoma. Br J Clin Pharmacol. 2024 Dec 18. doi: 10.1111/bcp.16367.
18. Zheng L#, Shimeng Liu#, Liu Z, Cao C, Xue W, Chen Y*, Liu J*. Eliciting medication preferences of patients with type 2 diabetes under different insurance coverages in China. Front Public Health. 2024 Oct 25;12:1413642. doi: 10.3389/fpubh.2024.1413642.
19. Shimeng Liu, Yuanyuan Gu*, Yi Yang, Elizabeth Schroeder, Yingyao Chen*. Tackling brain drain at Chinese CDCs: understanding job preferences of public health doctoral students using a discrete choice experiment survey. 2022, Human Resources Health. 2022;20(1):46. 
20. Shimeng Liu, Liu Jing, Yu Yijiang, Si Lei, Tang CX, Liu Zhigang, Chen Yingyao*. What Is Valued Most by Patients With Type 2 Diabetes Mellitus When Selecting Second-Line Antihyperglycemic Medications in China. Front Pharmacol. 2021;12:802897. 
21. Shimeng Liu, Chen Yingyao*, Li Shunping, Xu Ningze, Tang Chengxiang, Wei Yan. What Are the Important Factors Influencing the Recruitment and Retention of Doctoral Students in a Public Health Setting? A Discrete Choice Experiment Survey in China. Int J Environ Res Public Health. 2021;18(18):9474.
22. Shimeng Liu, Li S*, Li Y, Wang H, Zhao J, Chen G. Job preferences for healthcare administration students in China: A discrete choice experiment. PLoS One. 2019 Jan 25;14(1):e0211345. 
23. Shimeng Liu, Li S*, Yang R, Liu T, Chen G. Job preferences for medical students in China: A discrete choice experiment. Medicine (Baltimore). 2018 Sep;97(38):e12358. 
24. Ni Z, Zhu X, Guo J, Xie S*, Shimeng Liu*, Yang X*. Preferences for home-based care services during China's long-term care market transition: evidence from a discrete choice experiment. BMC Health Serv Res. 2025 May 17;25(1):713. doi: 10.1186/s12913-025-12853-z.
25. 陶颖, 刘世蒙*, 陈英耀*.优化陈述性偏好研究的属性确定过程：基于优劣尺度法[J]. 中国循证医学杂志, 2024(06).
26. 周善炎,陈英耀,徐子安,项予良, 刘世蒙*. 肿瘤电场联合替莫唑胺治疗胶质母细胞瘤的快速卫生技术评估, 中国医院管理, 2024(06).
27. 徐子安,陈英耀,周善炎, 项予良, 刘世蒙*.基于CiteSpace的肿瘤电场疗法治疗胶质母细胞瘤文献可视化分析[J].循证护理,2024,10(05):880-886.
28. 刘世蒙,杨毅,孙辉,明坚,陈英耀.患者偏好证据应用于卫生技术评估的价值、方法及挑战[J].中国卫生政策研究,2022,15(05):52-58.
29. 刘世蒙,夏志远,傅佩芬,赵培,李吟枫,陈娜,魏亚楠,杜诚勇,牟文轩,陈英耀^D.乳腺癌患者中心静脉输液装置选择偏好和支付意愿初步分析[J].中国循证医学杂志,2022,22(04):380-386.
30. 刘世蒙,陈英耀.上海市某高校公共卫生相关专业博士研究生就业偏好分析[J].医学与社会,2022,35(04):7-11.
31. 刘世蒙,李福明,明坚,魏艳,刘柳,陈英耀.卫生技术评估与审慎评议的国际经验及借鉴[J].中国医疗保险,2021(09):71-75.
32. 刘世蒙,刘静,谢士钰,柯雄,陈英耀.我国三级公立医院绩效考核指标评分方法分析[J].中国卫生资源,2021,24(03):268-271.
33. 刘世蒙,夏志远,魏艳,王丽英,陈英耀.离散选择实验在中心静脉输液装置选择偏好中的需求及应用分析[J].中国药物经济学,2021,16(01):5-9.
34. 刘世蒙,李顺平,杨毅,唐程翔,陈英耀.离散选择实验应用于2型糖尿病患者治疗偏好的文献分析[J].中国药房,2020,31(20):2524-2531.
35. 刘世蒙,谢士钰,刘静,柯雄,陈英耀.我国三级公立医院绩效考核主要问题及对策分析[J].中华医院管理杂志,2020,36(10):793-797.

1. 国家自然科学基金青年项目，主持（2025）
2. 教育部人文社科青年基金项目，主持（2023）
3. 上海市超级博士后，主持（2022）
4. 中国医药教育协会竞争性专项课题，主持（2023）
5. 国家卫健委卫生经济与政策研究重点实验室种子基金，主持（2025）
6. 国家自然科学基金面上项目，参与（2021）